🇺🇸 mesuximide in United States

41 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 41

Most-reported reactions

1. Thrombocytopenia — 7 reports (17.07%)
2. Fall — 5 reports (12.2%)
3. Hospitalisation — 5 reports (12.2%)
4. Ataxia — 4 reports (9.76%)
5. Haemodialysis — 4 reports (9.76%)
6. Nausea — 4 reports (9.76%)
7. Somnolence — 4 reports (9.76%)
8. Drug Interaction — 3 reports (7.32%)
9. General Physical Health Deterioration — 3 reports (7.32%)
10. Bradyphrenia — 2 reports (4.88%)

Source database →

Frequently asked questions

Is mesuximide approved in United States?

mesuximide does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for mesuximide in United States?

Assistance Publique - Hôpitaux de Paris is the originator. The local marketing authorisation holder may differ — check the official source linked above.